Automated LIII Lipoprotein Analyzer HLC-729LP II

Tosoh Begins Sales of Automated LIII Lipoprotein Analyzer HLC-729LP II
Tosoh has announced the January start of sales of its new lipoprotein analyzer, the HLC-729LP II. This automated LIII lipoprotein analyzer boasts speedy and accurate measurements of high-density lipoprotein (HDL), of low-density lipoprotein (LDL), and of very low-density lipoprotein (VLDL) cholesterol—important clinical tests for the diagnosis and treatment of high cholesterol. The HLC-729LP II demonstrates superior separation capabilities and analytical precision compared with the popular electrophoresis method.
Tosoh’s HLC-729LP II lipoprotein analyzer measures lipoproteins in serum using a high-performance liquid chromatography (HPLC) process. That process separates the different densities of cholesterol and measures their concentration based on coloring elicited using an enzymatic reaction. Individual tests take only 5.2 minutes and provide accurate typing of high blood cholesterol based on the World Health Organization (WHO)’s classifications. The diagnostic reagent used in testing is the HLC-Test Tosoh Lipopack. It is estimated that up to 22 million Japanese have high blood cholesterol, putting that condition on a par with diabetes as a major lifestyle disease.
HDL cholesterol is considered “good” cholesterol because it prevents hardening of the arteries, while LDL cholesterol is known as “bad” cholesterol because it causes hardening of the arteries. Recently, VLDL cholesterol levels in the blood have also drawn attention because of the link between high VLDL levels and the risk of hardening of the arteries. VLDL levels increase with obesity, metabolic syndrome, and insulin resistance. The advent of Tosoh’s HLC-729LP II lipoprotein analyzer adds greatly to the ability to test for what is a growing problem worldwide.